POZEN — BIO CEO & Investor Conference 2013
30 slides from POZEN's conference presentation, Feb 12, 2013

Slide 1: BIO CEO & Investor Conference
Exhibit 99.1 BIO CEO & Investor Conference February 2013

Slide 2: Forward-Looking Statements
Forward-Looking Statements The following presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forw

Slide 3: POZEN's PA Franchise: Improving the Risk/Benefit Balance of Aspirin
POZEN ’s PAFranchise: Improving the Risk/Benefit Balance of Aspirin PA32540, PA8140, PA10040 and other PA product candidates are investigational new drugs. No claims, either expressed or implied, are made with respect to the safety or efficacy of the PA product candidates for the indications under i

Slide 4: Key Message Take-Aways for Today
Key Message Take-Aways for Today Targeting NDA for PA32540 and PA8140 by April 2013 Positive top-line PA32540 Phase 3 results Seeking US and ROW commercial partner(s) to commercialize PA32540 / PA8140 / PA10040 • Ideal partner brings strong commercial capabilities and financial resources, as well as

Slide 5: Longer Term Strategy Focused on Building Shareholder Value
Longer Term Strategy Focused on Building Shareholder Value POZEN intends to maximize bottom line contribution from the PA franchise Limit ancillary expenditures Evaluation of current pipeline opportunities ongoing Only move additional programs into Phase 3 when partnered Management will remain focus

Slide 6: PA32540: Positive Top-Line Results from Two Pivotal Phase 3 Studies
PA32540: PositiveTop-LineResultsfrom Two Pivotal Phase 3 Studies Two Phase 3 pivotal trials under SPA • Total of 1,049 patients • Treatment with either PA32540 or EC ASA 325 mg once daily Primary endpoint met • Cumulative observed incidence of gastric ulcers over six months Key secondary endpoints m

Slide 7: Significant Reduction of Gastric Ulcers, Gastro-duodenal Ulcers and Discontinuations with PA32540 at 6 Months
Significant Reduction of Gastric Ulcers, Gastro-duodenal Ulcers and Discontinuations with PA32540 at 6 Months 16 PA32540 EC ASA 325mg P < 0.001 14 71% P < 0.001 12 11.6 63% P < 0.001 10 82% 8.6 8.2 8 6 4 3.2 3.4 2 1.5 0 Gastric Ulcers Gastro-duodenal UlcersDiscontinuations: (Primary Endpoint) UGI AE

Slide 8: Bioavailability
Bioavailability Study PA32540-115 • The FDA has indicated that Study 115, together with additional information that will be submitted in the NDA, should constitute sufficient data to support the establishment of a bridge to Ecotrin ® (325 mg) Study PA8140-102 • Demonstratedthat PA8140hadcomparablebi

Slide 9: PA Commercial Opportunity
>> BOLDOUTLOOK PA Commercial Opportunity WIPOZEN

Slide 10: PACV: Addresses a High Unmet Medical Need
PACV:Addressesa HighUnmetMedicalNeed Large Patient base (U.S. alone) 1 • 24MM secondary prevention patients 2 • 60 -80%+ use daily aspirin already ACC & ACG 2008 * Clinical Consensus recommend PPIs for ASA-induced GI injury: 3 • 20% on low-dose aspirin are at risk for UGI AEs, e.g., gastric or duode

Slide 11: Payer Market Research Findings: PA32540 Strong Payer Acceptance at $1.00/day
PayerMarket ResearchFindings:PA32540 Strong PayerAcceptance at $1.00/day Payers’initial reservations not unexpected • “Both products are OTC or generic” • Many requested efficacy data vs. the separate components Affordable pricingchanged Payer view to positive • Pricingis the key component to intere

Slide 12: Physician Market Research Findings: PA32540 Strong Physician Interest
PhysicianMarket Research Findings: PA32540 Strong Physician Interest to RX at $1.00/day Positive reaction to affordability (~$1/day) Would prescribe PA32540 or PA8140 for about 30% - 40% of secondary prevention patients 80+% of physicians would prescribe PA instead of separate components Compliance

Slide 13: Patient Market Research Findings: PA32540 Significant Patient Interest
PatientMarket Research Findings: PA32540 Significant Patient Interest at ~$1.00/Day Patient Willingness to Pay ($ / Month) 52% ‘extremely’or ‘very’interested 100% 60% would ask their doctor about it 36% Willing to Pay at $30/month 75% 36% willing to pay • 46% on ASA+PPI $30/month 50% Cost/Month Toda

Slide 14: PA's Potential Commercial Advantages
PA’sPotential Commercial Advantages Affordable pricing(~$1.00/day) for a potentially life saving medication • Pricing at or near the sum of generic components remains profitable • Value of the product to be supported by a pharmaco-economic model Large target patient population Targeted physician aud

Slide 15: Modeling the US Market Opportunity for PA32540/PA8140
Modeling the US Market Opportunity for PA32540/PA8140 $1,800 • There are 24MM CV secondary $1,500 1 prevention patients in the US 2 $1,200 • 95%+ of them take aspirin • Doctors would prescribe $900 PA32540/PA8140 for 30-40% of 2 $600 secondary prevention patients • 36% of patients would be willing t

Slide 16: PA32540/PA8140: >$400 MM US Market Opportunity
PA32540/ PA8140: >$400 MM US Market Opportunity Coordinated delivery of aspirin and omeprazole Affordable and convenient vs. taking two separate Differentiation products Global expansion opportunity Additional patent applications filed could extend to protection to 2022 -2030 Targeted Secondary prev

Slide 17: PA Products are Protected by a Robust Patent Position
PAProducts are Protected by a Robust Patent Position ‘A pharmaceutical composition in unit dosage form comprising an enteric-coated NSAID and a non-enteric- coated acid inhibitor formulated for coordinated release’ Two US Patents issued (expire 2/28/2023) • 6,926,907 issued 8/9/2005: Rights ex-aspir

Slide 18: Aspirin Use in Cancer
18 Aspirin Use in Cancer >> BOLDOUTLOOK IMPOZEN

Slide 19: Consider the Benefit/Risk Profile of ASA in Cancer
Consider the Benefit/Risk Profile of ASA in Cancer Benefits Risks • Strong anti-tumor effect • Risk profile primarily related demonstrated in various to antiplatelet activity and GI animal models toxicity • Compelling evidence for a • Perhaps the most well life prolonging effect of ASA known safety

Slide 20: Cancer and ASA: What Is Being Studied
Cancer and ASA: What Is Being Studied 20

Slide 21: Cancer and ASA: What Is Being Said
Cancer and ASA: What Is Being Said Benefits: Based on solid evidence, daily aspirin for at least 5 years reduces CRC incidence and mortality. This is based on two reports of extended follow-up of two RCTs and meta-analysis of observational studies. A third report that adds extended follow-up of an a

Slide 22: Cancer and ASA: What Is Being Said
Cancer and ASA: What Is Being Said The American Cancer Society does not currently recommend taking aspirin as a colon cancer prevention measure, Jacobs emphasizes. "Aspirin, even at low doses, substantially increases the risk of serious, occasionally fatal, gastrointestinal bleeding," he says. "Curr

Slide 23: Cancer and ASA: What Is Being Written
Cancer and ASA: What Is Being Written 23

Slide 24: Ongoing Clinical Studies with a Focus on Determining Aspirin's Effect on Cancer Outcomes
Ongoing Clinical Studies with a Focus on Determining Aspirin’s Effect on Cancer Outcomes* Protocol Title Study Period Sponsor Estimated Enrollment Aspirin for Dukes C and High Risk Dukes 2007-2019 NationalCancerCentre,Singapore 2,660 B Colorectal Cancers Universityof Oxford The Effect Of Aspirin On

Slide 25: Financial Overview
25 Financial Overview >> BOLDOUTLOOK IMPOZEN

Slide 26: VIMOVO Sales Growth in Q4 and 2012
VIMOVO Sales Growth in Q4 and 2012 Growth Growth $ (millions) Q4 vs. Q3 2012 vs. 2011 US VIMOVO Sales* $6m 79% $25m 19% ROW VIMOVO Sales* $12m 24% $40m 208% Global Sales* $18m 38% $65m 91% * As reported by AstraZeneca on 1/31/2013 26

Slide 27: Key Financial Facts
Key Financial Facts Financial Overview Net Cash at 6/30/12 $95.3 Million Net Cash at 9/30/12 $92.3 Million Shares Outstanding 30 Million Market Cap –2/8/13 $171 Million Self funding since IPO in 2000 2012 Results to be Reported 3/6/2013 27

Slide 28: Key Message Take-Aways for Today
Key Message Take-Aways for Today Targeting NDA for PA32540 and PA8140 by April 2013 Positive top-line PA32540 Phase 3 results Seeking US and ROW commercial partner(s) to commercialize PA32540 / PA8140 / PA10040 • Ideal partner brings strong commercial capabilities and financial resources, as well as

Slide 29: BIO CEO & Investor Conference
BIO CEO & Investor Conference February 2013

Slide 30: PA32540: Substantial Market Research Conducted with Key Stakeholders
PA32540: SubstantialMarket Research Conducted with Key Stakeholders* Payers Health Care Providers Patients (N=148) (N=4,000+) (N=2,600+) • Managed Care • Qual. Product Profile Testing & Forecast • Patient Incidence • Qual. Positioning, Attribute Testing & Forecast Advisory Panel Study Update • Payer
Source: SEC EDGAR · 8-K filed Feb 12, 2013



